U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H13NO2
Molecular Weight 167.205
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 3-O-METHYLDOPAMINE

SMILES

COC1=CC(CCN)=CC=C1O

InChI

InChIKey=DIVQKHQLANKJQO-UHFFFAOYSA-N
InChI=1S/C9H13NO2/c1-12-9-6-7(4-5-10)2-3-8(9)11/h2-3,6,11H,4-5,10H2,1H3

HIDE SMILES / InChI
3-Methoxytyramine (3-MT) is a human trace amine that occurs as a metabolite of the neurotransmitter dopamine. It has been shown to act as an agonist of human TAAR1, and an inhibitor of mitochondrial respiration. 3-MT has garnered research interest for its potential links and implications to Parkinson's disease and other Neurological disorders.

CNS Activity

Curator's Comment: CNS Active; but limited capacity to penetrate BBB.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q96RJ0
Gene ID: 134864.0
Gene Symbol: TAAR1
Target Organism: Homo sapiens (Human)
700.0 nM [EC50]
19.6 mM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Postmortal accumulation of 3-methoxytyramine in brain.
1974
Determination of urinary normetanephrine, metanephrine, and 3-methoxytyramine by liquid chromatography, with amperometric detection.
1977 Jul
Determination of catecholamines and their 3-O-methylated metabolites in urine by mass fragmentography with use of deuterated internal standards.
1979 Mar
Determination of catecholamines by radioenzymatic assay using ion-pair liquid chromatography.
1981 Apr 10
Melanoma detection by enzyme-radioimmunoassay of L-dopa, dopamine, and 3-O-methyldopamine in urine.
1981 Jan
Postmortem accumulation of 3-methoxytyramine in the brain.
1984 Aug 23
Extractive acylation and mass spectrometric assay of 3-methoxytyramine, normetanephrine, and metanephrine in cerebrospinal fluid.
1985 Sep
Increased monoamine metabolite concentrations and cholinesterase activities in cerebrospinal fluid of patients with acute stroke.
1987 Dec
Ketanserin reduces a particular monoamine pool in peripheral tissues.
1989 Mar
Analysis of S-nitroso-N-acetylpenicillamine effects on dopamine release in the striatum of freely moving rats: role of endogenous ascorbic acid and oxidative stress.
2001 Feb
Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis.
2002 Jun
Determination of catecholamines and metanephrines in urine by capillary electrophoresis-electrospray ionization-time-of-flight mass spectrometry.
2002 Sep 5
Sources and significance of plasma levels of catechols and their metabolites in humans.
2003 Jun
Inhibitory phenolic amides on lipopolysaccharide-induced nitric oxide production in RAW 264.7 cells from Beta vulgaris var. cicla seeds.
2003 Sep
Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off.
2004 Jun
Assessment of O-methylated catecholamine levels in plasma and urine for diagnosis of autonomic disorders.
2004 Nov 30
The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence.
2004 Oct
Metabolism of homovanillamine to homovanillic acid in guinea pig liver slices.
2005
Enhanced dopamine uptake in the striatum following repeated restraint stress.
2005 Sep 1
Isolation and identification of phase II enzyme-inducing agents from nonpolar extracts of green onion (Allium spp.).
2006 Nov 1
Autologous bone marrow transplanation for extramedullary plasmacytoma presenting as adrenal incidentaloma.
2009 May-Jun
Generation and characterization of conditional heparin-binding EGF-like growth factor knockout mice.
2009 Oct 14
Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands.
2009 Oct 23
Further evidence for aberrant prefrontal salience coding in schizophrenia.
2010
Low penetrance of a SDHB mutation in a large Dutch paraganglioma family.
2010 Jun 11
Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice.
2010 Jun 8
In utero exposure to a low concentration of diesel exhaust affects spontaneous locomotor activity and monoaminergic system in male mice.
2010 Mar 23
Attenuation of circulatory shock and cerebral ischemia injury in heat stroke by combination treatment with dexamethasone and hydroxyethyl starch.
2010 Oct 11
Patents

Sample Use Guides

Locomotor activity of DAT-KO and WT mice was measured in an Omnitech CCDigiscan. To assess effects of 3-MT in normal and TAAR1-KO mice, the animals were placed in the locomotor activity chamber and 30 min later various doses of 3-MT were administered i.c.v. over 4 minutes. After infusion, animals were put back into experimental chamber and behavior was monitored for 90 min after administration. 3-MT induced significant behavioral activation in DDD mice. Striatal tissue was collected from DDD mice treated with 36 µg of 3-MT 30 minutes after administration was analyzed for ERK activity. 3-MT caused a significant increase in the level of phosphorylated Erk2, thus indicating that certain receptor-mediated processes in striatal cells are affected by this treatment.
Route of Administration: Other
Mitochondria were isolated from whole brains of Sprague-Dawley rats. Mitochondria were suspended in 1 mL of incubation buffer containing 0.095MKCl, 0.075Mmannitol,0.025Msucrose, 0.005MKH2PO4, 0.020MTris-HCl, 0.001MEGTA, pH 7.4 (adjusted with KOH) at a final concentration of between 0.40 and 0.80 mg protein/mL. Malate and pyruvate were added to a final concentration of 10 mM. Oxygen consumption was carried out at 30°C in a closed chamber containing a Clark type oxygen electrode connected to a YSI model5300 oxygen monitor. Following a 10-minute incubation, resting conditions (no ADP) were monitored for 5 minutes, followed by the addition of ADP (0.25 mMfinal concentration) and measurement of active respiration. ADP depleted respiration was also monitored. Pre-incubation with the mitochondrial inhibitor 3-Methoxytyramine (3-MT) was carried out for15 min at 30°C prior to addition of ADP. Incubation with 3-MT was carried out in the dark for the first 10 minutes. IC50measurements represent the millimolar concentration of inhibitor required to inhibit 50% malate/pyruvate supported respiration compared with controls containing no inhibitor following a 15-min incubation at 30°C. 3-MT was found to inhibit brain mitochondrial respiration by MAO-dependent and -independent mechanisms. The IC50 of mitochondrial respiratory inhibition for 3-MT was determined to be 19.6 mM.
Name Type Language
3-O-METHYLDOPAMINE
Systematic Name English
4-(2-AMINOETHYL)-2-METHOXYPHENOL
Systematic Name English
4-HYDROXY-3-METHOXY-.BETA.-PHENETHYLAMINE
Systematic Name English
DOPAMINE HYDROCHLORIDE IMPURITY B [EP IMPURITY]
Common Name English
4-HYDROXY-3-METHOXYPHENYLETHYLAMINE
Systematic Name English
PHENOL, 4-(2-AMINOETHYL)-2-METHOXY-
Systematic Name English
HOMOVANILLINAMINE
Common Name English
HYDROXY-3-METHOXYPHENETHYLAMINE, 4-
Systematic Name English
2-METHOXY-4-(2-AMINOETHYL)PHENOL
Systematic Name English
4-HYDROXY-3-METHOXY-2-PHENETHYLAMINE
Systematic Name English
3-METHOXY-P-TYRAMINE
Common Name English
3-METHOXYTYRAMINE
Systematic Name English
GUAIACOL, 4-(2-AMINOETHYL)-
Systematic Name English
2-(4-HYDROXY-3-METHOXYPHENYL)ETHYLAMINE
Systematic Name English
4-HYDROXY-3-METHOXYPHENETHYLAMINE
Systematic Name English
HOMOVANILLYLAMINE
Systematic Name English
DOPAMINE IMPURITY B [EP IMPURITY]
Common Name English
Classification Tree Code System Code
LOINC 80156-3
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
LOINC 40409-5
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
LOINC 54343-9
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
LOINC 50140-3
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
LOINC 50139-5
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
LOINC 48381-8
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
LOINC 54344-7
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
LOINC 48380-0
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
LOINC 32618-1
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
Code System Code Type Description
MESH
C001746
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
PRIMARY
PUBCHEM
1669
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
PRIMARY
FDA UNII
JCH2767EDP
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
PRIMARY
WIKIPEDIA
3-Methoxytyramine
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
PRIMARY
CAS
554-52-9
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
PRIMARY
RXCUI
1742513
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
PRIMARY
EPA CompTox
DTXSID40862189
Created by admin on Sat Dec 16 18:54:30 GMT 2023 , Edited by admin on Sat Dec 16 18:54:30 GMT 2023
PRIMARY